

**Date: 13.08.2022**

To,  
**BSE Limited**  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir/Madam

**Sub: Outcome of Board meeting held on 13.08.2022**

**Unit: Decipher Labs Limited ; Scrip Code 524752**

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Decipher Labs Limited held on Saturday, 13.08.2022 at 05.00 p.m. at the registered office of the company at 4th Floor, Plot No. 94, Sagar Society, Banjara Hills, Road No. 2, Hyderabad – 500034, Telangana the following were considered and approved:

1. Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30.06.2022. **(Enclosed)**.
2. Limited Review Report (Standalone and Consolidated) for the quarter ended 30.06.2022. **(Enclosed)**.
3. Resignation of Mr. Janaki Ram Ajarapu as Director of the Company w.e.f. 13.08.2022 **(annexure enclosed)**.
4. Appointment of Mr. G. Venkateswara Rao (DIN: 02147615) as an Additional Director (Independent Category) of the Company w.e.f. 13.08.2022**(annexure enclosed)**.

The meeting concluded at 06:00 p.m.

This is for the information and records of the Exchange.

Thanking you.

Yours sincerely,

**For DECIPHER LABS LIMITED**

  
Sushant Mohan Lal

**DIRECTOR**

DIN: 01227151



Encl: as above

**DECIPHER LABS LIMITED** (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

**Consolidated Unaudited Financial Results For the Quarter ended 30 June 2022**

*All amounts in ₹ Lakhs, unless otherwise stated*

Particulars	Quarter ended			Year Ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Unaudited	Unaudited	Audited	Audited
I. Revenue from operations	1,261.92	2,328.77	1,339.61	6,532.24
II. Other income	686.36	16.27	11.07	767.40
<b>III. Total revenue (I + II)</b>	<b>1,948.27</b>	<b>2,345.04</b>	<b>1,350.68</b>	<b>7,299.64</b>
<b>IV. Expenses</b>	-	-	-	-
Purchase of Stock-in-Trade	31.50	-	-	15.53
Project Management Cost	-	719.17	-	719.17
Changes in inventories of finished goods and stock in trade	-	-	-	-
Employee benefits expense	1,063.18	1,170.94	1,146.44	4,748.68
Finance costs	11.36	13.90	12.51	47.66
Depreciation and amortisation expense	9.76	19.84	22.23	86.66
Other expenses	241.48	176.06	77.70	446.34
<b>Total expenses</b>	<b>1,357.28</b>	<b>2,099.91</b>	<b>1,258.88</b>	<b>6,064.04</b>
<b>V. Profit/(Loss) before tax (III - IV)</b>	<b>590.99</b>	<b>245.13</b>	<b>91.80</b>	<b>1,235.60</b>
<b>VI. Tax expense:</b>				
(1) Current tax	-	50.49	1.18	170.44
(2) Deferred tax	0.13	(0.24)	24.24	(73.97)
(3) Tax of earlier years	-	(0.01)	-	0.75
<b>VII. Profit/(Loss) for the period (V-VI)</b>	<b>590.86</b>	<b>194.89</b>	<b>66.38</b>	<b>1,138.38</b>
<b>VIII. Other comprehensive income</b>				
Items that will be reclassified to statement of profit and loss	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	57.96	35.74	19.80	56.09
<b>IX. Total comprehensive income for the year</b>	<b>648.82</b>	<b>230.63</b>	<b>86.18</b>	<b>1,194.47</b>
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
<b>X. Earning per equity share</b>				
(1) Basic	<b>5.85</b>	<b>1.93</b>	<b>0.66</b>	<b>11.27</b>
(2) Diluted	5.85	1.93	0.66	11.27
<b>Notes</b>				
1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.				
<b>Segment Information:</b>				
Particulars	Quarter ended			Year Ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Unaudited	Unaudited	Audited	Audited
<b>Segment Revenue</b>				
a) Manufacturing and Trading of Pharmaceutical drugs	45.00	38.80	-	68.82
b) Consultancy Services	1,216.92	3,629.58	1,339.61	6,463.42
<b>Total Sales</b>	<b>1,261.92</b>	<b>3,668.38</b>	<b>1,339.61</b>	<b>6,532.24</b>
Less: Inter Segment Revenue	-	-	-	-
<b>Total Revenue from Operations</b>	<b>1,261.92</b>	<b>3,668.38</b>	<b>1,339.61</b>	<b>6,532.24</b>
<b>Segment Result (Profit Before Tax and Interest from each Segment)</b>				
a) Manufacturing and Trading of Pharmaceutical drugs	21.48	(3.93)	-	2.72
b) Consultancy Services	580.87	(761.91)	104.31	255.66
<b>Total</b>	<b>602.35</b>	<b>(765.84)</b>	<b>104.31</b>	<b>258.38</b>
Less: Interest	11.36	13.59	12.51	47.66
<b>Total Profit before tax</b>	<b>590.99</b>	<b>(779.43)</b>	<b>91.80</b>	<b>210.72</b>

<b>Capital employed (Segment assets - segment liabilities)</b>				
<b>Segment assets</b>				
a) Manufacturing and trading of Pharmaceutical drugs	306.53	261.13	287.49	261.13
b) Consultancy Services	3,761.04	3,933.17	3,538.02	3,933.17
<b>Total Assets</b>	<b>4,067.57</b>	<b>4,194.30</b>	<b>3,825.51</b>	<b>4,194.30</b>
<b>Segment liabilities</b>				
a) Manufacturing and trading of Pharmaceutical drugs	12.24	8.17	21.01	8.17
b) Consultancy Services	990.00	1,770.21	2,349.63	1,770.21
<b>Total Liabilities</b>	<b>1,002.24</b>	<b>1,778.38</b>	<b>2,370.64</b>	<b>1,778.38</b>

2. The above results for the Quarter ended 30 June 2022 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13.08.2022.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder & in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The above results as of 30.06.2022 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA.

5. The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

6. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



**For and on behalf of the Board**

S M Lal

**DIRECTOR**

DIN: 01227151

Place: Hyderabad

Date: 13.08.2022



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of  
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure  
Requirements) Regulations, 2015

Review Report to The Board of Directors  
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiary, Decipher Software Solutions LLC, USA (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2022 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the subsidiary Decipher Software Solutions LLC, USA
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiary referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.




Ramanatham & Rao  
Chartered Accountants

6. We did not review the interim financial results of one subsidiary, Decipher Software Solutions LLC, USA included in the consolidated unaudited financial results whose interim financial results reflect total revenue of Rs.1209.02 lakhs, total net profit after tax of Rs.586.53 lakhs and total comprehensive Income of Rs.57.96 lakhs for the quarter ended 30<sup>th</sup> June, 2022, as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of this subsidiary is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao  
Chartered accountants  
(Firm Registration No.S-2934)



K.Sreenivasan  
Partner  
Membership No.206421

UDIN: 22206421AOYDKQ7281  
Place : Secunderabad  
Date : 13.08.2022



**DECIPHER LABS LIMITED** (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034  
 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

**Statement of Standalone Financial Results For the Quarter Ended 30th June, 2022**

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	52.90	24.46	18.35	98.84
II. Other income	0.58	3.23	0.46	4.59
<b>III.Total revenue (I + II)</b>	<b>53.49</b>	<b>27.69</b>	<b>18.81</b>	<b>103.43</b>
<b>IV. Expenses</b>				
Purchase of Stock in trade	31.50	-	-	15.53
Employee benefits expense	4.05	4.46	6.74	23.32
Finance Costs	-	-	0.10	-
Depreciation expense	1.47	1.41	1.17	5.01
Other expenses	12.01	8.87	5.20	23.78
<b>Total expenses</b>	<b>49.02</b>	<b>14.74</b>	<b>13.21</b>	<b>67.64</b>
<b>V. Profit before tax (III - IV)</b>	<b>4.46</b>	<b>12.95</b>	<b>5.60</b>	<b>35.79</b>
<b>VI. Tax expense:</b>				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.13	(0.37)	0.02	(0.25)
<b>VII. Profit/(Loss) for the period (V-VI)</b>	<b>4.33</b>	<b>13.32</b>	<b>5.58</b>	<b>36.04</b>
<b>VIII. Other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>IX. Total comprehensive income for the year</b>	<b>4.33</b>	<b>13.32</b>	<b>5.58</b>	<b>36.04</b>
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
<b>X. Earning per equity share</b>				
(1) Basic	0.04	0.13	0.06	0.36
(2) Diluted	0.04	0.13	0.06	0.36

**Notes**

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information: Particulars	Quarter ended			Year Ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Unaudited	Audited	Audited	Audited
<b>Segment Revenue</b>				
a) Manufacturing and Trading of Pharmaceutical drugs	45.00	-	-	68.82
b) Consultancy Services	7.90	24.46	18.35	30.02
<b>Total Sales</b>	<b>52.90</b>	<b>24.46</b>	<b>18.35</b>	<b>98.84</b>
Less: Inter Segment Revenue	-	-	-	-
<b>Total Revenue from Operations</b>	<b>52.90</b>	<b>24.46</b>	<b>18.35</b>	<b>98.84</b>
<b>Segment Result (Profit Before Tax and Interest from each Segment)</b>				
a) Manufacturing and Trading of Pharmaceutical drugs	3.80	-	-	24.92
b) Consultancy Services	0.67	12.95	5.70	10.87
<b>Total</b>	<b>4.46</b>	<b>12.95</b>	<b>5.70</b>	<b>35.79</b>
Less: Interest	-	-	0.10	-
<b>Total Profit before tax</b>	<b>4.46</b>	<b>12.95</b>	<b>5.60</b>	<b>35.79</b>
<b>Capital employed (Segment assets - segment liabilities)</b>				
<b>Segment assets</b>				
a) Manufacturing and trading of Pharmaceutical drugs	1,146.53	1,146.31	1,122.67	1,146.31
b) Consultancy Services	22.47	14.04	20.42	14.04
<b>Total Assets</b>	<b>1,168.99</b>	<b>1,160.35</b>	<b>1,143.09</b>	<b>1,160.35</b>
<b>Segment liabilities</b>				
a) Manufacturing and trading of Pharmaceutical drugs	12.24	8.04	21.01	8.04
b) Consultancy Services	-	-	-	-
<b>Total Liabilities</b>	<b>12.24</b>	<b>8.04</b>	<b>21.01</b>	<b>8.04</b>

2. The above results for the quarter ended 30 June 2022 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13.08.2022.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



S.M.Lal  
**DIRECTOR**

DIN: 01227151

Place: Hyderabad  
 Date: 13.08.2022



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Review Report to The Board of Directors

Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of unaudited financial results of Decipher labs Limited (Formerly known as Combat Drugs Limited) (the "Company") for the quarter ended 30<sup>th</sup> June, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao  
Chartered accountants  
(Firm Registration No.S-2934)

K.Sreenivasan  
Partner  
Membership No.206421

UDIN: 22206421AOYDFK4413

Place : Secunderabad

Date : 13.08.2022



**Annexure**

**[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated September 9, 2015]**

Particulars	Mr. Janaki Ram Ajarapu	Mr. G. Venkateswara Rao
<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Resignation	Appointment
<b>Date of appointment &amp; term of appointment/ resignation</b>	Resigned 13.08.2022 w.e.f.	Appointed w.e.f. 13.08.2022 up to ensuing general meeting
<b>Brief Profile</b>	NA	He is a Graduate in Commerce (B.COM) from Osmania University. He has also done Bachelor of Law from Marathwada University and is highly experienced in Management of companies.
<b>Disclosure of relationships between directors (in case of appointment of a director)</b>	NA	NA
<b>Information as required under circular No. LIST/COMP/14/2018-19 dated 20.06.2018</b>	NA	Mr. G. Venkateswara Rao is not debarred from holding office of a director by virtue of any SEBI Order or any other such authority.
<b>Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any</b>	Nil	Nil

